Lower respiratory tract infections treated with bacampicillin: a dose comparison.

Abstract

In an open multicentre study of bacampicillin (Penglobe), a new orally well absorb ed prodrug of ampicillin, 516 patients with acute exacerbations of chronic bronchitis or pneumonia were treated by a group of Belgian pneumologists or internists. Bacampicillin was given in a dosage regimen of 400 mg or 800 mg three times daily. In patients with acute exacerbations of chronic bronchitis the clinical success rate was high, over 95% in both groups. An improvement in the sputum purulence score was seen in 93% of the patients with an initially purulent sputum and 69% had a normal mucoid sputum at follow-up. The clinical success rate in patients with pneumonia was also similar in both dosage groups with success rates over 96%. The total number of patients with adverse reactions was not more than 5-4%, of which the majority were considered mild or moderate. Each type of side-effect occurred in a frequency of 1-2% or less. There were no differences between the two dosage regiments as regards the frequency of side-effects indicates a remarkably good tolerance of bacampicillin also with the higher dosage.

• Authors: J Sjövall
• Journal: The Journal of international medical research (J Int Med Res) Vol. 5 Issue 5 Pg. 313-21 ( 1977) ISSN: 0300-0605 [Print] England
• PMID: 913859 (Publication Type: Journal Article)

Chemical References

• Ampicillin
• bacampicillin

Topics

• Acute Disease
• Adult
• Aged
• Ampicillin (administration & dosage, analogs & derivatives, therapeutic use)
• Bronchitis (drug therapy)
• Chronic Disease
• Female
• Humans
• Male
• Middle Aged
• Pneumonia (drug therapy)